ANI Pharmaceuticals said Thursday it initiated a phase 4 trial at Massachusetts General Hospital to evaluate the safety and efficacy of two dosing levels of purified Cortrophin gel in treating acute gout flares.
The company said Cortrophin gel is approved for short-term use as an adjunct therapy during acute episodes of gouty arthritis but is not for intravenous administration.
The study aims to further assess its clinical benefits and inform optimal dosing strategies, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.